Does Insurance Cover GLP-1 Weight-Loss Drugs? Coverage Rules and How to Appeal a Denial

Why there’s no single yes-or-no answer

The most common question people ask about Wegovy, Zepbound, and the rest of the GLP-1 family is also the hardest to answer cleanly: “Will my insurance cover it?” The honest reply is that it depends on two variables that have nothing to do with the drug itself - what kind of plan you have, and what condition it’s being prescribed for.

The same molecule can be covered generously, covered with hurdles, or not covered at all, depending on whether you’re on a large employer plan, an individual marketplace plan, Medicare, or Medicaid - and whether your prescription is written for obesity, type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea. A diabetes prescription for semaglutide (Ozempic) is treated very differently by insurers than a weight-loss prescription for the same drug under the Wegovy label, even though the active ingredient is identical.

That “indication split” is the single most important thing to understand before you start. Coverage for GLP-1s used to treat a recognized medical condition other than obesity is widespread and stable. Coverage for GLP-1s used purely for weight management is patchy, shrinking on the commercial side, and historically blocked on the government side. Everything below is organized around that distinction.

Note: This page is about how coverage works - the rules, the paperwork, and the programs. For sticker prices and cash-pay routes, see the dedicated cost pages linked throughout.

Commercial and employer plans

This is where most working-age Americans get their coverage, and it’s also where the picture has shifted most in 2026 - generally toward less access for weight-loss use.

Across the commercial market, the number of people with no coverage at all for weight-loss GLP-1s has climbed sharply. Research tracking these plans found that, entering 2026, tens of millions more people lost commercial coverage for Wegovy and Zepbound than the year before. And among those who do keep coverage, the large majority - over 88% - still have to clear additional requirements before a prescription gets paid.

How coverage varies by employer size

Coverage tracks closely with how big your employer is. Large employers are far more likely to include weight-loss medication as a benefit; small employers rarely do. The rough breakdown looks like this:

• Very large employers (20,000+ workers): the majority cover GLP-1s for weight loss.
• Large employers (5,000+ workers): roughly four in ten cover them.
• Smaller employers (a few hundred workers): only a small minority do.

If you’re on a “Blue Cross” or “UnitedHealthcare” or “Aetna” plan, the insurer’s name tells you almost nothing on its own. Blue Cross Blue Shield, for instance, is a federation of dozens of independent companies, and each designs its own formularies. What ultimately decides your coverage is the specific plan design your employer bought, not the logo on your card.

Self-funded plans and why coverage is shrinking

A large share of US workers are on self-funded employer plans, where the employer pays claims directly and the insurer just administers them. These plans are governed by the federal ERISA law, which does not require employers to cover weight-loss drugs. That gives employers wide latitude to add, restrict, or drop the benefit - and courts have generally sided with that discretion.

Faced with the cost of covering a popular, long-term, expensive class of drugs, many employers have tried step therapy, prior authorization, and lifestyle-program prerequisites, then concluded none of those guardrails slowed spending enough - and dropped weight-loss coverage while keeping diabetes coverage intact. Several insurers also pared back their standard formularies during 2025 and 2026, removing or restricting weight-loss GLP-1s for individual and small-group members.

Prior authorization: what plans typically ask for

If your plan does cover weight-loss GLP-1s, expect a prior authorization (PA). This is the documentation hurdle a provider’s office submits before the plan agrees to pay. Common requirements include:

• A qualifying BMI - usually 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, or sleep apnea.
• Documented prior attempts at weight management - often three to six months of diet, lifestyle, or program participation on record. Some plans have raised this to a full six months.
• Step therapy - trying a lower-cost option first (an older anti-obesity drug, for example) before a GLP-1 is approved.
• Formulary tier and quantity limits - even when approved, the drug may sit on a specialty tier with higher cost-sharing.

The practical upshot: coverage often hinges less on whether the drug is “on the list” and more on whether your records satisfy the PA criteria.

Medicare: the statutory wall and the new Bridge

Medicare is a special case because of a decades-old rule. By federal statute, Medicare Part D cannot cover a drug prescribed for weight loss - weight-loss medications are in an excluded category, alongside a handful of others. Changing that would take an act of Congress.

There are two important exceptions to know:

1. Other indications are covered normally. If a GLP-1 is prescribed for an FDA-approved use other than weight loss, Part D can cover it under its usual rules. In practice that means Ozempic and Mounjaro for type 2 diabetes, Wegovy to reduce cardiovascular risk in people with established heart disease, and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. These still run through your plan’s formulary, prior authorization, and cost-sharing - and in 2026, Part D caps your total out-of-pocket drug spending at $2,100 for the year once you reach it.

2. The temporary Medicare GLP-1 Bridge. This is the big 2026 development. Starting July 1, 2026, the CMS-run Medicare GLP-1 Bridge gives eligible Part D members access to specific GLP-1s for obesity - Wegovy, Zepbound, and Foundayo - for a $50 copayment per 30-day supply. Key details:

• You must be enrolled in a Part D plan (standalone or through a Medicare Advantage drug plan), but the Bridge operates outside the normal Part D benefit.
• Eligibility is based on BMI - broadly, 35 or higher on its own, or 27 or higher with additional clinical criteria.
• It’s time-limited. Originally planned to run only through the end of 2026, it has been extended through December 31, 2027, while the longer-term BALANCE Model demonstration was delayed.
• Low-income subsidy (Extra Help) cost-sharing reductions generally can’t be applied to Bridge fills, so the $50 copay is a flat figure for everyone in the program.
• CMS has been releasing operational details - including the prior authorization process - in the run-up to launch.

If you already qualify for coverage through a standard indication (diabetes, CVD, sleep apnea), you keep using your regular Part D benefit for that - the Bridge is specifically the obesity-only pathway.

Medicaid: optional, and getting narrower

Medicaid coverage of GLP-1s splits along the same indication line. Under federal rules, state Medicaid programs must cover GLP-1s for medically accepted FDA-approved indications other than weight loss - so diabetes coverage is effectively required. But covering them for obesity is optional, left to each state.

As of early 2026, only about 13 states covered GLP-1s for obesity, down from 16 the year before - a retreat driven by the cost of coverage and tight state budgets. Some large states tightened access further: California’s Medi-Cal program, for example, removed Wegovy, Zepbound, and Saxenda for weight-loss indications at the start of 2026, while continuing to allow them for specific covered conditions like cardiovascular disease, MASH, or sleep apnea.

If you’re on Medicaid, the realistic expectation is that diabetes and other recognized indications are covered, but obesity coverage depends entirely on your state - and even where it exists, prior authorization and strict criteria usually apply.

Manufacturer savings cards (and why government plans are excluded)

For people with commercial insurance, manufacturer savings cards are often the single biggest lever on out-of-pocket cost.

• A Wegovy savings card can bring eligible commercially insured patients down to as little as $0-$25 per month when the plan covers the drug.
• A Zepbound savings card works similarly, though Eli Lilly tightened the program in 2026 - reducing the maximum monthly benefit, adding a household-income cap, and cutting the lifetime number of fills. Covered patients can still pay as little as $25, while those whose plan doesn’t cover the drug pay a higher self-pay rate through the same card.

Two rules trip people up:

They don’t work with government insurance. Manufacturer copay cards are barred from use with Medicare, Medicaid, TRICARE, or VA coverage. If you have any of those, the card isn’t an option - the Medicare GLP-1 Bridge or a patient-assistance program is the relevant path instead.

They’re not stackable with each other. Manufacturers treat each program as a separate lane, not a pile of discounts to combine. You generally pick one route - commercial insurance plus the savings card, or direct self-pay, or a patient-assistance program - and optimize within it. You can’t, for example, layer a savings card on top of the manufacturer’s already-discounted direct-pay price.

HSA, FSA, and bridging a gap in coverage

If you’re paying out of pocket - whether because you’re uninsured for the drug, in a deductible phase, or paying a specialty-tier copay - pre-tax accounts can help. GLP-1s are generally HSA- and FSA-eligible when prescribed by a licensed provider to treat a diagnosed condition such as obesity or diabetes. The eligibility test is the prescription and medical necessity, not the brand on the box, so the same logic applies whether you’re filling Ozempic, Wegovy, or Zepbound. Using pre-tax dollars effectively discounts the cost by your marginal tax rate.

Some people who lose coverage look at compounded semaglutide or tirzepatide as a cheaper route. That’s a more complicated legal and safety picture than it appears - the regulatory status changed substantially once the official shortages resolved - so it’s worth reading the dedicated explainer before assuming it’s a clean alternative.

Insurance denied Wegovy or Zepbound? How to appeal

A denial isn’t always the end of the road. Many initial denials turn on missing paperwork rather than a hard “no,” and plans must give you a written process to challenge them. But the appeal window is short, and the reason on the letter decides whether an appeal is worth your time. Work through it in this order.

Step 1: read the denial letter for the reason and the deadline

The written denial has to state the specific reason for the decision and tell you how to appeal. Find two things before anything else: the exact reason (often a code plus a sentence) and the appeal deadline, which is typically somewhere between 30 and 180 days from the date on the letter. If you only have a verbal “it was denied” from the pharmacy, ask the plan for the written notice. Then sort the reason into one of these buckets:

• Missing or incomplete documentation (no BMI on file, no record of diet attempts, wrong diagnosis code). The most common and the most winnable - the fix is resubmitting with the records the plan asked for.
• Step therapy (you must try a cheaper drug first). Winnable if you can document that the required drug was already tried, failed, caused side effects, or is contraindicated for you.
• BMI or comorbidity criteria not met. Winnable if your chart simply doesn’t show a weight-related condition you actually have, or your BMI history wasn’t included. Hard to win if you genuinely sit outside the plan’s thresholds.
• Non-formulary or non-preferred drug. Ask for a formulary exception rather than a standard appeal, and explain why the preferred alternative isn’t appropriate.
• Plan exclusion for weight-loss drugs. This is a benefit design decision, not a medical judgement, and it usually cannot be overturned on appeal. Don’t burn your window here. Instead, ask your prescriber whether you qualify under a covered indication (type 2 diabetes, established cardiovascular disease, or obstructive sleep apnea), check whether your employer offers an optional coverage rider, and move to the fallback options below.

Step 2: decide who writes the appeal

There are three routes, and they’re not mutually exclusive:

1. Your prescriber appeals. This carries the most weight. The office can file a written appeal with your records and request a peer-to-peer review, where your doctor speaks directly with the plan’s medical reviewer. Many prescriber-led appeals are settled at that call.
2. You file a member appeal yourself. Every plan allows this. It works best when the denial was about paperwork or a factual error, and when you attach a supporting letter from your prescriber.
3. You use an appeal service. Some clinics and third-party services handle the whole process for a fee or as part of their program. Worth it if your prescriber’s office won’t engage or you’ve already lost one round.

Step 3: what a winning appeal letter contains

The plan judged you against its own written criteria, so the letter should quote those criteria back and answer each one with evidence:

• BMI history with dates, showing you meet the threshold (and did at the time of the prescription).
• Weight-related conditions on the record - hypertension, high cholesterol, prediabetes, sleep apnea, fatty liver, joint disease - with the diagnosis dates.
• Prior attempts: diet and lifestyle programs, and any earlier weight-loss medications, each with dates and outcomes.
• Why alternatives are inappropriate: contraindications, side effects, or failure of the step-therapy drug.
• A clear statement of medical necessity from the prescriber, ideally built on the manufacturer’s coverage request letter template, which both Novo Nordisk and Eli Lilly publish for providers.
• Clinical guideline citations supporting GLP-1 therapy for your BMI and risk profile.

Keep a copy of everything you send, note the date, and ask the plan for written confirmation that the appeal was received. If a delay would seriously harm your health, you can request an expedited appeal, which the plan must decide far faster.

Step 4: if the internal appeal is denied too

Once you’ve exhausted the plan’s internal appeals, you generally have the right to an independent external review. The final denial letter must explain how to request it and the deadline for doing so. For fully insured plans this runs through your state’s insurance regulator or an independent review organisation; for self-funded employer plans it runs through a federal external review process. The reviewer’s decision is binding on the plan, and external review is where documentation-based denials that the plan kept refusing often get reversed.

If the appeal fails: your fallback options

If the drug is excluded outright or external review goes against you, stop fighting the plan and change lanes:

• A covered indication. If you have type 2 diabetes, heart disease, or sleep apnea, a prescription written for that condition may be covered when the obesity prescription wasn’t.
• Manufacturer self-pay and savings programs. Both major manufacturers now sell Wegovy and Zepbound directly at cash prices well below list, and the savings cards offer a higher self-pay rate for commercially insured patients whose plan doesn’t cover the drug. See Wegovy cost and access, Zepbound cost and access, and TrumpRx and direct-to-consumer GLP-1 pricing.
• Compounded semaglutide or tirzepatide. Cheaper, but the legal and quality picture changed once the shortages ended. Read is compounded semaglutide or tirzepatide still legal before treating it as a clean substitute.
• A clinic that handles the paperwork. Telehealth and in-person weight-loss clinics that prescribe GLP-1s day in, day out tend to have staff who submit prior authorizations, run appeals, and know which cash-pay route fits when coverage fails. If you’d rather not fight this alone, use the enquiry form on this page and we’ll match you with a licensed clinic that manages prior authorizations and appeals for its patients and can quote you a self-pay price if insurance stays closed. Our guides on how to get semaglutide and how to get tirzepatide explain what the consult involves.

What’s changing next

The landscape is moving quickly. Beyond the Medicare GLP-1 Bridge, manufacturers have announced list-price cuts taking effect in 2027 - Novo Nordisk said it would reduce Wegovy and Ozempic list prices significantly - and Medicare is negotiating prices on some of these drugs for future years. Direct-to-consumer cash programs from both major manufacturers have also reshaped what “no insurance” actually costs. None of this is static, so treat any specific figure here as current as of this page’s update date and verify your own plan’s formulary before you count on it.

The single most useful move, in every scenario, is to call the number on your insurance card and ask three specific questions: Is this drug on my formulary? Is it covered for my diagnosis? And what does the prior authorization require? Those answers - not a general rule - decide what you’ll actually pay.